FDA Regulation of Cannabis and CBD

FDA Regulation of Cannabis and CBD

CBD and cannabis products have recently become of major interest to both consumers and healthcare brands as they research the benefits of CBD oil for several common ailments. Unfortunately, if Cannabis or CBD oil products are going to be marketed as health products, then there is a specific process that the Food and Drug Administration (FDA) must adhere to in order to make sure that the products follow guidelines.

Although the FDA is still currently going through the process of legalizing the marketing aspects for CBD oil in regard to its status as a dietary supplement, they have announced that there is an active process in place for doing so.

According to Harvard Health, “a significant safety concern with CBD is that it is primarily marketed and sold as a supplement, not a medication. Currently, the FDA does not regulate the safety and purity of dietary supplements. So, you cannot know for sure that the product you buy has active ingredients at the dose listed on the label. In addition, the product may contain other (unknown) elements. We also don”t know the most effective therapeutic dose of CBD for any particular medical condition.”

One of the main purposes of the FDA is to substantiate that any claims made by various companies are legitimate. For this reason, until the FDA has completed its regulations for CBD products, companies are supposed to be conscious of the wording used in their marketing campaigns.

At this time, there is very little scientific data available for the health benefits of various CBD products. This is largely because CBD is a cannabis-derived product, which was illegal prior to 2018 when hemp products were officially passed as a legal substance.

Unfortunately, without significant data available, the FDA’s process will be slowed down significantly while more research is completed.

While the FDA acknowledges that they are actively working on an approved method for building FDA approved CBD oil products, they are also keenly aware of the risks that are involved with the drug as well. The FDA is a bit concerned about the potential impact that CBD products can have on liver health. Further, they would like more insight into the ways that CBD oil interacts with other medications.

The FDA needs insight into a number of different considerations before making a final decision regarding the industry of CBD.

These factors are summarized below:
  • Impacts of prolonged CBD use
  • How are the risks of CBD triggered?
  • Insight into the different methods of consumption
  • CBD impact on children/teens
  • Effects on fertility
  • Safety during pregnancy or breastfeeding

Insight into all of this information will help the FDA make a more informed decision about whether or not CBD products can be advertised as a health item. The FDA agrees that the public is extremely interested in the potential market of FDA approved CBD and prescription health products.

In order to reach the goal, the FDA will begin to complete the necessary research into CBD products. Exploring each of the major concerns summarized below, the FDA hopes to have the data that they need in order to safely set the guidelines and expectations for CBD products in the United States.

The FDA is particularly interested in gathering information about the vaping products that are currently being marketed. As an agency concerned with the health of the citizens of this country, the FDA is particularly concerned with how the marketing might tempt young teens to partake in a potentially toxic activity.

Regardless, the important steps that need to be taken in order to build the market for CBD products is now in place. The FDA expects that this process is going to take some time. Unfortunately, they cannot accurately estimate the amount of time that will be needed in order to gather the data and the information required for the CBD market to be opened up and fully legal.

Although, most CBD advocates are quite simply happy to know that the FDA is finally doing their part to look into making this giant step toward normalization of cannabis derived products.